The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Banerji, Udai
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Mar 2010 - 1613-23 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1557-3265
10.1158/1078-0432.CCR-09-2483 doi
Administration, Oral
Adult
Aged
Antineoplastic Agents--administration & dosage
Benzimidazoles--administration & dosage
Capsules
Female
Humans
MAP Kinase Kinase 1--antagonists & inhibitors
MAP Kinase Kinase 2--antagonists & inhibitors
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms--drug therapy
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Mar 2010 - 1613-23 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1557-3265
10.1158/1078-0432.CCR-09-2483 doi
Administration, Oral
Adult
Aged
Antineoplastic Agents--administration & dosage
Benzimidazoles--administration & dosage
Capsules
Female
Humans
MAP Kinase Kinase 1--antagonists & inhibitors
MAP Kinase Kinase 2--antagonists & inhibitors
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms--drug therapy